The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Tixantone     1-(2-diethylaminoethylamino)- 4-methyl...

Synonyms: Lucanthon, Lucantona, LUCANTHONE, Lucanthonum, Miracil D, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Miracil D


High impact information on Miracil D


Biological context of Miracil D


Anatomical context of Miracil D


Associations of Miracil D with other chemical compounds


Gene context of Miracil D

  • The ability of lucanthone to inhibit the normal repair of abasic sites might reflect inhibition of apurinic/apyrimidinic endonuclease (HAP1) by the drug, thereby preventing an early step in the base excision repair pathway [19].
  • Butyrylcholinesterase inhibition by miracil D and other compounds [20].
  • Pretreatment of human leukemia THP-1 cells with heat shock protein Hsp70 (Hsp70) protected them from the cell-lethal effects of the topoisomerase II inhibitor, lucanthone and from ionizing radiation [21].
  • Given these initial findings, it would be of interest to further develop lucanthone as an APE1 inhibitor through the use of structure-function studies as a means of enhancing the sensitization of tumors to chemotherapeutic agents [5].
  • We report that lucanthone inhibits the repair activity of APE1, but not its redox function or exonuclease activity on mismatched nucleotides [5].

Analytical, diagnostic and therapeutic context of Miracil D

  • Size determinations were made of patients' brain metastases from magnetic resonance images or by computed tomography before and after treatment with 30 Gy whole brain radiation alone or with lucanthone [13].
  • METHODS AND MATERIALS: Lucanthone was incubated with human topoisomerases II and I together with their plasmid substrates, to determine if lucanthone interfered with the catalytic activities of topoisomerases and if it enhanced the formation of DNA strand breaks, as determined by agarose gel electrophoresis of the resultant plasmid forms [22].
  • Schistosomicide drugs are used as ligands to isolate the target antigens of schistosome by affinity chromatography [23].
  • Worm recovery by perfusion of the porto-mesenteric system, followed by counting and a morphometric study of the parasite, allowed the conclusion that the relative resistance of the larval stages of S. mansoni to schistosomicide drugs, demonstrated in primary infections, also persists when the host is already infected [24].
  • The application of a known radiosensitizer (lucanthone) combined with 13.5 rd whole-body irradiation on day 8 of gestation showed enhanced teratogenic action compared to treatment with each of the agents alone [25].


  1. The adjuvant effect of lucanthone (miracil D) in clinical radiation therapy. Turner, S., Bases, R., Pearlman, A., Nobler, M., Kabakow, B. Radiology. (1975) [Pubmed]
  2. Lucanthone modification of cyclophosphamide toxicity in the Chinese hamster. Milligan, A.J., Whittington, R., Leeper, D.B. Int. J. Radiat. Oncol. Biol. Phys. (1982) [Pubmed]
  3. Microsomal activation to mutagens of antischistosomal methyl thioxanthenones and initial tests on a possibly non-mutagenic analogue. Hartman, P.E., Hulbert, P.B., Bueding, E., Taylor, D.D. Mutat. Res. (1975) [Pubmed]
  4. Detection of mammalian cell mutagens in urine from carcinogen-dosed mice. Amacher, D.E., Turner, G.N., Ellis, J.H. Mutat. Res. (1981) [Pubmed]
  5. Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Luo, M., Kelley, M.R. Anticancer Res. (2004) [Pubmed]
  6. Effect of lucanthone hydrochloride on the radiation response of intestine and bone marrow of the Chinese hamster. Milligan, A.J., Katz, H.R., Leeper, D.B. J. Natl. Cancer Inst. (1978) [Pubmed]
  7. Effects of lucanthone on the sedimentation properties of DNA from HeLa cells. Bases, R., Leifer, A., Rozycki, H., Blake, C., Neubort, S. Cancer Res. (1977) [Pubmed]
  8. Effect of lucanthone (miracil D) on transcription of ribosomal RNA genes from Tetrahymena in vivo and in vitro. Westergaard, O., Gocke, E., Nielsen, O.F., Leer, J.C. Nucleic Acids Res. (1979) [Pubmed]
  9. Stimulation of topoisomerase II-mediated DNA cleavage by an indazole analogue of lucanthone. Dassonneville, L., Bailly, C. Biochem. Pharmacol. (1999) [Pubmed]
  10. The effect of lucanthone on sublethal radiation damage, in vivo. Milligan, A.J., Metz, J.A., Leeper, D.B. Int. J. Radiat. Oncol. Biol. Phys. (1984) [Pubmed]
  11. Mutagenicity of hycanthone in Drosophila: additional results and a comparison with some analogs. Kramers, P.G. Mutat. Res. (1981) [Pubmed]
  12. Effect of nucleic-acid-binding compounds on the hydrolytic activity of various ribonucleases. Holbrook, D.J., Wichard, L.P., Washington, M.E. Eur. J. Biochem. (1975) [Pubmed]
  13. Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. Del Rowe, J.D., Bello, J., Mitnick, R., Sood, B., Filippi, C., Moran, J., Freeman, K., Mendez, F., Bases, R. Int. J. Radiat. Oncol. Biol. Phys. (1999) [Pubmed]
  14. Lucanthone as a radiosensitizing agent in the treatment of carcinoma of the cervix. Nobler, M.P., Scher, A.J. Int. J. Radiat. Oncol. Biol. Phys. (1978) [Pubmed]
  15. Effects of the schistosomicide 1,7-bis(p-aminophenoxy)heptane (153C51) on lysosomes and membrane stability. Watts, S.D., Atkins, A.M. Biochem. Pharmacol. (1979) [Pubmed]
  16. Proceedings: Interaction of tetracycline and lucanthone on radiation damage in mammalian embryos as dependent on LET (experiments with pions). Fritz-Niggli, H., Michel, C. Br. J. Cancer (1975) [Pubmed]
  17. Recovery of the hepatic drug-metabolizing capacity in mice infected with Schistosoma mansoni following curative chemotherapy with the schistosomicide 4-isothiocyano-4'-nitro-diphenylamine (CGP 4540). Cha, Y.N., Bueding, E. Am. J. Trop. Med. Hyg. (1978) [Pubmed]
  18. Preliminary investigations of some derivatives of oxamniquine. Karekezi, C.W., Lucas, P.D., Marples, B.A., Salt, W.G. Journal of chemotherapy (Florence, Italy) (1995) [Pubmed]
  19. Abasic sites in DNA of HeLa cells induced by lucanthone. Mendez, F., Goldman, J.D., Bases, R.E. Cancer Invest. (2002) [Pubmed]
  20. Butyrylcholinesterase inhibition by miracil D and other compounds. Verdier, J.S., Wolfe, A.D. Biochem. Pharmacol. (1986) [Pubmed]
  21. Clonogenicity of human leukemic cells protected from cell-lethal agents by heat shock protein 70. Bases, R. Cell Stress Chaperones (2005) [Pubmed]
  22. Topoisomerase inhibition by lucanthone, an adjuvant in radiation therapy. Bases, R.E., Mendez, F. Int. J. Radiat. Oncol. Biol. Phys. (1997) [Pubmed]
  23. Drugs as ligands of immunogenic molecules in parasites: an approach to the isolation of target-antigens. Bout, D., Dupas, H., Capron, M., Tran-Van-Ky, P., Capron, A. J. Immunol. Methods (1977) [Pubmed]
  24. Chemotherapeutic effects on larval stages of Schistosoma mansoni during infection and re-infection of mice. Silva, L.M., Menezes, R.M., de Oliveira, S.A., Andrade, Z.A. Rev. Soc. Bras. Med. Trop. (2003) [Pubmed]
  25. Effects of low-dose irradiation with x-rays and pi-mesons on embryos of two different mouse strains. Michel, C., Fritz-Niggli, H., Blattmann, H., Cordt-Riehle, I. Strahlentherapie. (1977) [Pubmed]
WikiGenes - Universities